Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOUBLE PRO-TECT Alport
NCT05944016Phase 3Recruiting
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Mar 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in Alport syndrome, sponsored by Universitätsmedizin Göttingen. Started Mar 2024; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on NCT05944016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05944016.